Combined Therapy Improved Care Of Patients With Type 2 Diabetes Proper Use Of New Oral Medications Evaluated

March 26, 1998

NEW HAVEN, Conn., March 26, 1998-When patients with type 2 diabetes took two new medications together, rather than separately, they experienced further improvement in controlling their blood glucose levels, according to a new study conducted by researchers at Yale University School of Medicine and the Howard Hughes Medical Institute at Yale.

"The medications that we studied-metformin and troglitazone-act in different ways in the human body and were equally effective in lowering patients' blood glucose levels," explains Gerald I. Shulman, M.D., Ph.D., professor of medicine (endocrinology) and of cellular and molecular physiology at Yale and an investigator with the Howard Hughes Medical Institute. "The combined therapy was logical and reversed two abnormalities that patients with this disorder experience. Metformin acted primarily to decrease the patients' liver glucose production, while troglitazone worked primarily to enhance the ability of the patients' muscle to respond to insulin and take up glucose."

The findings are reported in the March 26 issue of The New England Journal of Medicine, published by the Massachusetts Medical Society. The study itself was conducted in Yale's federally supported General Clinical Research Center. Glucose, a simple sugar, serves as an important source of energy in the human body, as well as an important source of energy for the brain. People with diabetes experience higher than normal blood glucose levels, which can lead to complications.

Type 2 diabetes, the most common type of diabetes, is considered to be the leading cause of blindness, renal failure and loss of limb, according to the American Diabetes Association (ADA). It also is the fourth leading cause of death. Approximately $85 billion a year are estimated to be spent on direct diabetes care.

Type 2 diabetes affects about 15 million Americans, the ADA estimates. Approximately seven million Americans have been diagnosed with this disease, and another eight million remain undiagnosed.

In the study, Yale and HHMI physicians, scientists and nurses evaluated the efficacy and physiologic effects of these two oral medications in 29 patients who suffer from type 2 diabetes, a chronic disease that requires individuals to be greatly involved in their own daily medical care. For three months, the patients were treated with only one medication, and then for an additional three months simultaneously with both medications. During the study, the patients were prescribed a diet designed to maintain their base-line body weight.

"The future of treatment in our type 2 diabetic patients will likely be combination therapy since no single agent will reverse all of the abnormalities seen in our diabetic patients," Dr. Shulman explains. "Therefore, it is essential that we understand the mechanism by which these novel oral medications lower patients' blood glucose. We then will be able to combine them in a rational fashion for effective treatment."

According to Silvio E. Inzucchi, M.D., assistant professor of medicine (endocrinology), results of this study offer new treatment options for our patients with type 2 diabetes.

Besides Drs. Inzucchi and Shulman, co-authors are David G. Maggs, M.D.; Geralyn R. Spollett, A.P.R.N.; Stephanie L. Page, R.N.; Frances S. Rife, R.N.; and Veronika Walton, B.A..

The study was supported, in part, by grants from the National Institute of Diabetes and Digestive and Kidney Diseases, a component of the National Institutes of Health, and Warner-Lambert Co., the parent company of Parke-Davis. Both Drs. Inzucchi and Shulman are consultants to Parke-Davis.
P.O. BOX 7612
NEW HAVEN, CT 06519-0612

Yale University School of Medicine

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to